{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:48:30Z","timestamp":1792633710067,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.metabol.2021.154728","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T20:37:59Z","timestamp":1612989479000},"page":"154728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity"],"prefix":"10.1016","volume":"118","author":[{"given":"Zijing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhongZe","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154728_bb0005","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1053\/j.gastro.2009.02.038","article-title":"Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154728_bb0010","first-page":"15","article-title":"Diagnosis and treatment of gallstone disease","volume":"259","author":"Lee","year":"2015","journal-title":"Practitioner"},{"key":"10.1016\/j.metabol.2021.154728_bb0015","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1053\/j.gastro.2011.02.055","article-title":"PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts","volume":"140","author":"He","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154728_bb0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-2275(20)37603-3","volume":"37","author":"Wang","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154728_bb0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/j.2040-4603.2013.tb00517.x","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.metabol.2021.154728_bb0030","doi-asserted-by":"crossref","unstructured":"Graf GA, Yu L, Li W-P, Gerard R, Tuma PL, Cohen JC, Hobbs HHJJoBC. ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion.278:48275\u201348282.","DOI":"10.1074\/jbc.M310223200"},{"key":"10.1016\/j.metabol.2021.154728_bb0035","doi-asserted-by":"crossref","unstructured":"Yu L, Gupta S, Xu F, Liverman ADB, Moschetta A, Mangelsdorf DJ, Repa JJ, et al. Expression of ABCG5 and ABCG8 Is Required for Regulation of Biliary Cholesterol Secretion.280:8742\u20138747.","DOI":"10.1074\/jbc.M411080200"},{"key":"10.1016\/j.metabol.2021.154728_bb0040","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1042\/BC20040088","article-title":"Biliary lipids, water and cholesterol gallstones","volume":"97","author":"van Erpecum","year":"2005","journal-title":"Biol Cell"},{"key":"10.1016\/j.metabol.2021.154728_bb0045","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1016\/S0021-9258(20)89517-9","article-title":"Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis","volume":"266","author":"Cali","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0050","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.mam.2012.07.004","article-title":"The solute carrier family 10 (SLC10): beyond bile acid transport","volume":"34","author":"Claro da Silva","year":"2013","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.metabol.2021.154728_bb0055","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.271.50.32269","article-title":"Molecular cloning and expression of rabbit sterol 12alpha-hydroxylase","volume":"271","author":"Eggertsen","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0060","first-page":"407","article-title":"Intestinal bile acid transport: biology, physiology, and pathophysiology","volume":"32","author":"Shneider","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.metabol.2021.154728_bb0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"key":"10.1016\/j.metabol.2021.154728_bb0070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2021.154728_bb0075","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154728_bb0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/s41591-019-0509-0","article-title":"Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome","volume":"25","author":"Qi","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154728_bb0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154728_bb0090","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00018-014-1805-y","article-title":"Nuclear bile acid signaling through the farnesoid X receptor","volume":"72","author":"Mazuy","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.metabol.2021.154728_bb0095","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.metabol.2021.154728_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.metabol.2021.154728_bb0105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154728_bb0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.metabol.2021.154728_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cmet.2019.09.016","article-title":"Adipocyte hypoxia-inducible factor 2alpha suppresses atherosclerosis by promoting adipose ceramide catabolism","volume":"30","author":"Zhang","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154728_bb0120","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2021.154728_bb0125","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154728_bb0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.gastro.2019.04.002","article-title":"Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide","volume":"157","author":"Karhus","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154728_bb0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/TP.0000000000002448","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, attenuates development of cardiac allograft vasculopathy in a murine heart transplant model","volume":"103","author":"Wang","year":"2019","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.metabol.2021.154728_bb0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-020-07088-5","article-title":"Glucagon-like peptide-1 analog liraglutide attenuates pressure-overload induced cardiac hypertrophy and apoptosis through activating ATP sensitive potassium channels","volume":"35","author":"Bai","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.metabol.2021.154728_bb0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2021.154728_bb0155","doi-asserted-by":"crossref","first-page":"33275","DOI":"10.1074\/jbc.M204935200","article-title":"Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine","volume":"277","author":"Madison","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0160","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0022-2275(20)40677-7","article-title":"Critical tables for calculating the cholesterol saturation of native bile","volume":"19","author":"Carey","year":"1978","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154728_bb0165","doi-asserted-by":"crossref","first-page":"48275","DOI":"10.1074\/jbc.M310223200","article-title":"ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion","volume":"278","author":"Graf","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0170","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1194\/jlr.R084244","article-title":"ABCG5 and ABCG8: more than a defense against xenosterols","volume":"59","author":"Patel","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154728_bb0175","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15505.1","article-title":"Recent advances in understanding and managing cholesterol gallstones","volume":"7","author":"Di Ciaula","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.metabol.2021.154728_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.metabol.2021.154728_bb0185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cmet.2015.01.007","article-title":"MAFG is a transcriptional repressor of bile acid synthesis and metabolism","volume":"21","author":"de Aguiar Vallim","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154728_bb0190","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ajpath.2016.12.013","article-title":"Activation of constitutive Androstane receptor prevents cholesterol gallstone formation","volume":"187","author":"Cheng","year":"2017","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2021.154728_bb0195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154728_bb0200","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of Liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154728_bb0205","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nexoe-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154728_bb0210","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154728_bb0215","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/hep.24107","article-title":"Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis","volume":"53","author":"Li","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2021.154728_bb0220","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0022-2275(20)32213-6","article-title":"Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding","volume":"42","author":"Schwarz","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2021.154728_bb0225","doi-asserted-by":"crossref","first-page":"42588","DOI":"10.1074\/jbc.M205117200","article-title":"Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet","volume":"277","author":"Chen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154728_bb0230","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/dom.12748","article-title":"Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154728_bb0235","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2021.154728_bb0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF02535021","article-title":"Effects of feeding chenodeoxycholic acid on metabolism of cholesterol and bile acids in germ-free rats","volume":"16","author":"Gustafsson","year":"1981","journal-title":"Lipids"},{"key":"10.1016\/j.metabol.2021.154728_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.apsb.2015.01.006","article-title":"The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics","volume":"5","author":"Ridlon","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.metabol.2021.154728_bb0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","article-title":"The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet","volume":"227","author":"Somm","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.metabol.2021.154728_bb0255","doi-asserted-by":"crossref","first-page":"33251","DOI":"10.1038\/srep33251","article-title":"Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2021.154728_bb0260","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1172\/JCI111301","article-title":"The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS)","volume":"73","author":"Grundy","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2021.154728_bb0265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/CS20110184","article-title":"Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications","volume":"121","author":"Roma","year":"2011","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2021.154728_bb0270","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm1138","article-title":"Prevention of cholesterol gallstone disease by FXR agonists in a mouse model","volume":"10","author":"Moschetta","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154728_bb0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.gtc.2010.02.003","article-title":"Epidemiology of gallstones","volume":"39","author":"Stinton","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.metabol.2021.154728_bb0280","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:26:51Z","timestamp":1758428811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":56,"alternative-id":["S0026049521000287"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154728","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154728"}}